P2Y11 Antagonist B7508: Advancing GPCR Signaling Research

Introduction and Principle: Targeting the P2Y11 Receptor in Cell Signaling

The P2Y11 antagonist (SKU: B7508), chemically known as sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate, is a highly selective G protein-coupled receptor antagonist developed for in-depth scientific research. The P2Y11 receptor, a member of the purinergic P2Y family, orchestrates diverse intracellular signaling cascades, including those regulating immune responses, inflammation, and cell migration. By antagonizing this receptor, B7508 offers researchers a precise cell signaling inhibitor for dissecting P2Y receptor signaling and related GPCR signaling pathways.

Interest in the P2Y11 signaling axis has surged due to its implication in disease states such as autoimmune disorders, neuroinflammation, and cancer metastasis. Notably, the Liu et al. (2021) study demonstrated that antagonizing P2Y11 reversed quinolinate phosphoribosyltransferase (QPRT)-induced invasiveness in breast cancer models, directly linking P2Y11 antagonism to modulation of the inflammation pathway and metastatic potential.

The P2Y11 antagonist is supplied as a stable beige solid (molecular weight: 986.84, C₃₇H₂₆N₄Na₄O₁₅S₄), water-soluble at <19.74 mg/mL, and should be stored at -20°C to ensure integrity. APExBIO, a trusted provider of research reagents, ensures optimal shipping and handling to preserve activity.

Step-by-Step Experimental Workflow for P2Y11 Antagonist Applications

1. Preparation and Handling

• Upon receipt, confirm the product's integrity (beige solid, intact packaging, shipped on blue ice).
• Dissolve in sterile, deionized water at concentrations up to 19.74 mg/mL; avoid exceeding solubility limits to prevent precipitation.
• Prepare aliquots for single-use; solutions are not recommended for long-term storage. Use freshly prepared solutions for maximal potency.
• Store unused solid at -20°C; minimize freeze-thaw cycles.

2. Cell-Based Assays

• Cultivate target cells (e.g., immune cells, breast cancer lines such as BT-20, MCF-7, MDA-MB-231) using standard protocols. Validate cell line identity via STR profiling to ensure reproducibility.
• Treat cultures with the P2Y11 antagonist at empirically determined concentrations (typical range: 1–10 μM; titration recommended). Include vehicle controls for baseline comparison.
• For co-treatment studies, apply P2Y11 antagonist alongside other inhibitors (e.g., Rho/ROCK/MLCK/PLC inhibitors) to dissect pathway interactions, as in Liu et al. (2021).
• Monitor endpoints such as cell migration (wound healing, transwell assays), invasion (Matrigel, Boyden chamber), cytokine release (ELISA), or downstream signaling (Western blot for myosin light chain phosphorylation, qPCR for inflammatory gene expression).

3. Data Acquisition and Analysis

• Quantify inhibition of target pathways using densitometry, migration/invasion indices, or cytokine quantification. In Liu et al., P2Y11 antagonism reduced breast cancer cell invasiveness by >40% and decreased myosin light chain phosphorylation, confirming efficacy.
• Apply statistical analysis to validate significance (ANOVA, t-test). Normalize to vehicle controls and include at least three biological replicates for robustness.

4. Reporting and Reproducibility

• Document chemical batch, preparation date, and concentration details in lab records and publications for transparency.
• Cross-reference results with established literature, such as the Immuneland review for mechanistic depth or the PR-171 workflow guide for protocol enhancements.

Advanced Applications and Comparative Advantages

Expanding Research Horizons

The P2Y11 antagonist (B7508) is pivotal for modulating inflammation pathway signaling in a spectrum of preclinical models:

• Autoimmune Disease Research: By inhibiting P2Y receptor signaling, researchers can delineate its role in T cell activation, differentiation, and cytokine storms, offering insights for novel immunotherapies [see PR-171 review].
• Cancer Metastasis: The antagonist is instrumental in uncovering how GPCR signaling pathway dysregulation contributes to tumor invasiveness and metastasis, as evidenced by the reversal of QPRT-driven migration in breast cancer cells (Liu et al., 2021).
• Neuroinflammation Studies: Leveraging the antagonist's selectivity, researchers can untangle purinergic signaling contributions to microglial activation and neurodegeneration.

Comparative Strengths

• High Selectivity: B7508 offers targeted inhibition of the P2Y11 receptor without significant off-target activity, enabling cleaner interpretation of pathway-specific results.
• Water Solubility: Facilitates integration into aqueous cell culture systems, reducing the risk of solvent-induced effects compared to less soluble analogs.
• Validated in Translational Models: Supported by published data and community reviews, including the AImmunity article, B7508 enables both basic and applied research from bench to in vivo systems.

This product thus complements existing tools for inflammation pathway modulation and extends the capabilities of researchers investigating GPCR signaling in complex disease models.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation occurs, verify that the concentration does not exceed 19.74 mg/mL. Gently warm (no higher than 37°C) and vortex to aid dissolution; never use organic solvents as this may alter activity.
• Loss of Activity: Avoid repeated freeze-thaw cycles. Prepare fresh aliquots for each experiment and keep solutions on ice during use. Do not store solutions longer than 24 hours.
• Variable Cellular Responses: Confirm cell line authentication and passage number. Some lines may exhibit altered receptor expression; validate via qPCR or immunostaining if responses are inconsistent.
• Assay Sensitivity: Optimize antagonist concentration via dose-response curves. Pilot studies suggest 1–10 μM yields robust P2Y11 inhibition without toxicity, but cell-type specific optimization is essential.
• Interfering Pathways: When dissecting complex networks (e.g., co-activation with other GPCRs), consider parallel control treatments with other pathway inhibitors or siRNA knockdown to confirm specificity.
• Batch Consistency: Always record APExBIO lot numbers and compare performance against previous batches if discrepancies arise.

Future Outlook: Unlocking New Frontiers in GPCR and P2Y11 Research

With the growing recognition of GPCR signaling pathway complexity in disease etiology, the P2Y11 antagonist B7508 is positioned to catalyze next-generation discoveries. Future directions include:

• Personalized Immunology: Mapping P2Y11-mediated responses in patient-derived immune cells to inform individualized therapeutic strategies.
• In Vivo Imaging and Pharmacokinetics: Developing labeled derivatives of B7508 for real-time receptor occupancy studies in animal models.
• Combination Therapies: Integrating P2Y11 antagonism with standard-of-care agents to assess synergistic effects in autoimmune disease and cancer models.
• Neurodegenerative Disease Mechanisms: Expanding into models of Alzheimer's and Parkinson's disease to clarify P2Y11’s role in neuroinflammation and synaptic regulation.

As evidenced by breakthroughs such as the QPRT study, the strategic application of selective antagonists like B7508 will continue to drive translational advances. Researchers are encouraged to explore the comprehensive P2Y11 antagonist product page for technical datasheets and ordering information.

Conclusion

The P2Y11 antagonist B7508, supplied by APExBIO, stands at the forefront of cell signaling inhibitor tools for unraveling the complexities of GPCR signaling in immunology, inflammation, cancer, and neurobiology. Its robust performance, high specificity, and validated protocols empower labs to generate reproducible, high-impact data across diverse fields. By integrating the troubleshooting tips and workflow enhancements outlined above, researchers can maximize the scientific value of this advanced reagent and accelerate the translation of bench discoveries into clinical insights.